8-KItem 4.01 · Accountant ChangeItem 9.01 · Financial Statements
INSULET CORP (PODD)

Insulet ($PODD) filed an 8‑K (Item 9.01) on Dec 19, 2025 — furnished Exhibit 16.1: letter from Grant…

Filed with the SEC on · Summarized by InvestorsBot

Insulet ($PODD) filed an 8‑K (Item 9.01) on Dec 19, 2025 — furnished Exhibit 16.1: letter from Grant Thornton LLP to the SEC (dated Dec 19, 2025) and Exhibit 104 (Inline XBRL cover page). Signed by CFO Flavia Pease. 📄 #SEC #audit #medtech

Investor note: Item 9.01 lists only an auditor letter (Grant Thornton LLP) as Exhibit 16.1 — the 8‑K text provides no additional disclosures. Review Exhibit 16.1 for any auditor commentary. 🧐 $PODD #investing #SEC

Filing pertains to "Financial Statements and Exhibits" — no new financial statements were attached, only the auditor correspondence and the Inline XBRL cover page (Exhibit 104). 📎 $PODD #SEC #medtech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from INSULET CORP

Insulet ($PODD) filed a Form 8‑K on Mar 12, 2026 furnishing a press release (Exhibit 99.1) dated Mar 12, 2026.

8-K · March 12, 2026

Mar 12, 2026: Insulet ($PODD) says voluntary medical-device correction; expects up to $40M of costs, all…

8-K · March 12, 2026

Insulet ($PODD) on Feb 27, 2026 entered a severance agreement with former CFO Ana M.

8-K · March 4, 2026

Insulet ($PODD) filed an 8‑K on Feb 18, 2026 furnishing a press release as Exhibit 99.1.

8-K · February 18, 2026

On Feb 13, 2026 Insulet's Board approved a $350M increase to the prior $125M share repurchase…

8-K · February 18, 2026

Insulet ($PODD) announced Q4 & full-year 2025 financial results on Feb 18, 2026 covering the period ended…

8-K · February 18, 2026